Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126677471 | 12667747 | 1 | I | 20160708 | 20160819 | 20160819 | EXP | PHHY2016BR097161 | NOVARTIS | 0.00 | M | Y | 70.00000 | KG | 20160819 | CN | COUNTRY NOT SPECIFIED | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126677471 | 12667747 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH 10 CM2) | Y | U | 674210 | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||
| 126677471 | 12667747 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH 10 CM2) | Y | U | 604210 | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||
| 126677471 | 12667747 | 3 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH 10 CM2) | Y | U | 022017 | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||
| 126677471 | 12667747 | 4 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH 10 CM2) | Y | U | 032015 | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126677471 | 12667747 | 1 | Apathy |
| 126677471 | 12667747 | 2 | Dementia Alzheimer's type |
| 126677471 | 12667747 | 3 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126677471 | 12667747 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126677471 | 12667747 | Application site erythema | |
| 126677471 | 12667747 | Application site hypersensitivity | |
| 126677471 | 12667747 | Application site vesicles | |
| 126677471 | 12667747 | Blister rupture | |
| 126677471 | 12667747 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |